F10
ENSG00000126218
Target class
Enzyme
Chromosome
13
Approved drugs
7
Clinical candidates (approved and in development)
14
- Approved drugs
- 7
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- No
- Other names
- fX
- Target name
- F10
- Gene name
- Coagulation factor X
- Gene symbol
- F10
- Protein name
- Coagulation factor X (EC 3.4.21.6) (Stuart factor) (Stuart-Prower factor) [Cleaved into: Factor X light chain; Factor X heavy chain; Activated factor Xa heavy chain]
- Gene biotype
- Protein coding
- Gene family
- Gla domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 45
- Highest tissue expression
- 75.53
- Tissue specificity (Gini)
- 0.591
- Tissue specificity (tau)
- 0.851
- KEGG gene identifiers
- hsa:2159
- Protein interaction confidence
- 0.847419
- Protein interaction partners
- 31
- R-HSA-159740
- R-HSA-159763
- R-HSA-159782
- R-HSA-9672383
- R-HSA-9672396
- R-HSA-9673202
- R-HSA-9769735
- R-HSA-9769739
- R-HSA-9769743
- End position
- 113149531
- Start position
- 113122788
- Chromosome
- 13
- Strand
- Forward
- Secreted.
- Tissue specificity (tau)
- 0.850685
- Expression inequality (Gini)
- 0.591147
Expression in transcripts per million
- Cervix - Ectocervix
- 75.53
- Liver
- 73.38
- Cervix - Endocervix
- 45.32
- Ovary
- 39.47
- Vagina
- 30.55
Expression in transcripts per million
- Cervix - Ectocervix75.53
- Liver73.38
- Cervix - Endocervix45.32
- Ovary39.47
- Vagina30.55
- Fallopian Tube29.79
- Adipose - Subcutaneous24.53
- Heart - Atrial Appendage23.45
- Skin - Sun Exposed (Lower leg)21.52
- Uterus20.81
- Lung19.98
- Artery - Aorta17.66
- Artery - Coronary17.6
- Bladder16.46
- Nerve - Tibial16.17
- Testis15.8
- Artery - Tibial14.98
- Prostate13.66
- Adipose - Visceral (Omentum)13.33
- Skin - Not Sun Exposed (Suprapubic)13.14
- Breast - Mammary Tissue12.86
- Esophagus - Gastroesophageal Junction12.75
- Cells - Cultured fibroblasts11.73
- Thyroid10.82
- Small Intestine - Terminal Ileum8.24
And 29 more, listed on the interactive page.
- GO:0007596
- GO:0030335
- GO:0032008
- GO:0005576
- GO:0005788
- GO:0005796
- GO:0005886
- GO:0009897
- GO:0004252
- GO:0005515
- GO:0005543
Related records
Trials (979)
- A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations
- A Clinical Study of KW-3357 in Patients With DIC
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344
- A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
- A Clinical Trial to Evaluate the Effect of Grapefruit Juice on the PK/PD of Edoxaban
- A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
- A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions
- A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers
- A Multi-center Study of Apixaban(APPROACH)
- A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
- A New Oral Treatment For Type II Diabetes Mellitus
- A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
- A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150
- A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet
- A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
- A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
Drugs (16)
- Antithrombin alfa Coagulation factor X inhibitor
- Apixaban Coagulation factor X inhibitor
- Bemiparin Coagulation factor X inhibitor
- Betrixaban Coagulation factor X inhibitor
- Coagulation factor X human Coagulation factor X exogenous protein
- Darexaban Coagulation factor X inhibitor
- Edoxaban Coagulation factor X inhibitor
- Edoxaban tosylate Coagulation factor X inhibitor
- Emicizumab Coagulation factor IX and X other
- Idrabiotaparinux sodium Coagulation factor X inhibitor
- Idraparinux Coagulation factor X inhibitor
- Idraparinux sodium Coagulation factor X inhibitor
- Letaxaban Coagulation factor X inhibitor
- Otamixaban Coagulation factor X inhibitor
- Prothrombin complex concentrate Coagulation factor X exogenous protein
- Rivaroxaban Coagulation factor X inhibitor